Evidence map›Paper›PMID 41315789›Full record

ArticleScientific reports2025

Mesenchymal stem cells-like as a prognostic biomarker in patients diagnosed with acute myeloid leukemia.

Tamara Castaño-Bonilla, Daniel Láinez-González, Juana Serrano, Mireia Atance, Raquel Mata, Cristina Serrano, Rocío Olivera, Rocío Salgado, Raquel Capellán, Gonzalo Castellanos and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Tamara Castaño-BonillaHematology Department, Hospital Universitario Fundación Jiménez Díaz, Avenida Reyes Católicos, 2, 28040, Madrid, Spain. tamara.castano@fjd.es.
Daniel Láinez-GonzálezInstituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid, Spain.
Juana SerranoInstituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid, Spain.
Mireia AtanceHematology Department, Hospital Universitario Fundación Jiménez Díaz, Avenida Reyes Católicos, 2, 28040, Madrid, Spain.
Raquel MataHematology Department, Hospital Universitario Fundación Jiménez Díaz, Avenida Reyes Católicos, 2, 28040, Madrid, Spain.
Cristina SerranoInmunology Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
Rocío OliveraInstituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid, Spain.
Rocío SalgadoHematology Department, Hospital Universitario Fundación Jiménez Díaz, Avenida Reyes Católicos, 2, 28040, Madrid, Spain.
Raquel CapellánHematology Department, Hospital Universitario Fundación Jiménez Díaz, Avenida Reyes Católicos, 2, 28040, Madrid, Spain.
Gonzalo CastellanosHematology Department, Hospital Universitario Fundación Jiménez Díaz, Avenida Reyes Católicos, 2, 28040, Madrid, Spain.
Carlos BlasHematology Department, Hospital Universitario Fundación Jiménez Díaz, Avenida Reyes Católicos, 2, 28040, Madrid, Spain.
Laura PardoHematology Department, Hospital Universitario Fundación Jiménez Díaz, Avenida Reyes Católicos, 2, 28040, Madrid, Spain.
Laura SolánHematology Department, Hospital Universitario Fundación Jiménez Díaz, Avenida Reyes Católicos, 2, 28040, Madrid, Spain.
Belén RosadoHematology Department, Hospital Universitario Rey Juan Carlos, Madrid, Spain.
María YusteHematology Department, Hospital Universitario General de Villalba, Madrid, Spain.
Pilar BeltranHematology Department, Hospital Universitario Infanta Elena, Madrid, Spain.
Alberto LázaroHematology Department, Hospital Clinic Barcelona, Barcelona, Spain.
Ignacio MahilloDepartment of Statistics, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
Eva OlivaInstituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid, Spain.
Pilar LlamasHematology Department, Hospital Universitario Fundación Jiménez Díaz, Avenida Reyes Católicos, 2, 28040, Madrid, Spain. pilar.beltran@quironsalud.es.
Juan M Alonso-DomínguezHematology Department, Hospital Universitario Fundación Jiménez Díaz, Avenida Reyes Católicos, 2, 28040, Madrid, Spain. juan.adominguez@fjd.es.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The bone marrow microenvironment influences acute myeloid leukemia (AML) progression. Mesenchymal stem cell-like (MSC-l) populations may exert tumor-modulating effects, but their prognostic role remains uncertain. We retrospectively analyzed 65 adult AML patients (excluding acute promyelocytic leukemia) treated with intensive chemotherapy between 2017 and 2024 at four Spanish institutions. MSC-l cells were identified in BM aspirates at end of treatment by multiparameter flow cytometry (CD13

Indexed as

Biomarkers, TumorLeukemia, Myeloid, AcuteMesenchymal Stem CellsAdultAgedFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesYoung AdultBiomarkers, TumorAcute myeloid leukemiaHematopoietic microenvironmentMesenchymal stem cellsMultiparameter flow cytometryPrognostic biomarker

Identifiers

PMID41315789
PMCPMC12663226

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.